Wednesday, 28 June 2017

Vetter enters into strategic agreement with Microdermics

15 June 2017 | News

Microdermics has successfully demonstrated the initial safety of its microneedle system, and is planning Phase 1 human clinical trials for vaccine and therapeutic delivery, to be initiated in 2017.

Vetter, a leading and innovative provider of aseptic prefilled drug delivery systems and Microdermics Inc., a Vancouver-based medical device company developing a novel hollow, metal microneedle drug and vaccine delivery system, have entered into a strategic cooperation agreement.

Microdermics microneedle technology is commercially scalable and capable of pain-free injections into the pharmacokinetically beneficial intradermal space, providing improved comfort and treatment to patients. Microdermics has successfully demonstrated the initial safety of its microneedle system, and is planning Phase 1 human clinical trials for vaccine and therapeutic delivery, to be initiated in 2017.

As a leading contract development and manufacturing organization (CDMO), Vetter offers its customers a beneficial service through a combination of device development and associated drug product manufacturing and packaging services. Vetter tries to integrate its customers in technological advancements as early as possible. By continuously participating in market development in innovative and proactive ways, the company is committed to acting with the goal of increasing patient convenience and compliance in mind.

Vetter’s vast experience with a wide variety of drug substances provides Microdermics with an invaluable opportunity for a successful development path for the microneedle drug delivery technology.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Will Asia- Pacific healthcare IT market hit the double digit growth in the next five years?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls